Comparative Pharmacology
Head-to-head clinical analysis: HALCION versus KLONOPIN RAPIDLY DISINTEGRATING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALCION versus KLONOPIN RAPIDLY DISINTEGRATING.
HALCION vs KLONOPIN RAPIDLY DISINTEGRATING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Category C
Category C
Benzodiazepine
Benzodiazepine